Bremelanotide (Vyleesi) offers a targeted approach for managing hypoactive sexual desire disorder (HSDD) in premenopausal women by acting on melanocortin receptors in the brain to enhance sexual motivation. Unlike other HSDD treatments, Bremelanotide is a melanocortin receptor agonist that primarily binds to receptors involved in behavior and arousal, stimulating dopamine release and boosting desire. Administered before sexual activity, it has shown a favorable impact on sexual interest and related distress. Bremelanotide stands out from alternative treatments by directly influencing arousal pathways rather than modifying serotonin or hormonal levels, providing a unique therapeutic option.
Hall, K. S. K., & Binik, Y. M. (2020). Principles and practice of sex therapy (6th ed.). The Guilford Press.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about PT-141 by Ultima Pharmaceuticals, consult with your doctor or healthcare professional.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Home
